LENZ Therapeutics (LENZ) Total Liabilities (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Total Liabilities data on file, last reported at $26.0 million in Q1 2026.

• Quarterly Total Liabilities rose 181.79% year-over-year to $26.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.0 million (up 181.79% YoY) and the FY2025 annual result came in at $21.5 million, up 91.95% from the prior year.
• Total Liabilities grew to $26.0 million in Q1 2026 per LENZ's latest filing, from $21.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $62.9 million in Q2 2023 and bottomed at $8.7 million in Q3 2024.
• The 5-year median for Total Liabilities is $18.4 million (2022), against an average of $22.9 million.
• The widest annual swing landed in 2023, when Total Liabilities jumped 310.29%; it then tumbled 85.97% in 2024.
• Tracing LENZ's Total Liabilities over 5 years: stood at $25.6 million in 2022, then declined by 23.09% to $19.7 million in 2023, then slumped by 43.04% to $11.2 million in 2024, then jumped by 91.95% to $21.5 million in 2025, then climbed by 20.92% to $26.0 million in 2026.
• Per Business Quant, the three latest LENZ Total Liabilities figures stand at $26.0 million (Q1 2026), $21.5 million (Q4 2025), and $16.8 million (Q3 2025).

Peer Comparison